BrightSpring Health Services, Inc. (BTSG) Q1 2026 Earnings Call Transcript – Image for illustrative purposes only (Image credits: Unsplash)
Louisville, Kentucky — BrightSpring Health Services Inc. delivered standout first-quarter performance in 2026, fueled by double-digit growth across its core segments. The company reported results from continuing operations, excluding its recently divested Community Living business, and surpassed Wall Street estimates on key metrics. Executives pointed to momentum in specialty pharmacy and home health as primary drivers during the May 1 earnings call.[1][2]
Key Financial Highlights Exceed Expectations
BrightSpring recorded total revenue of $3.6 billion from continuing operations, marking a 26 percent increase from the prior year. This figure topped analyst projections and reflected strong contributions from both Pharmacy Solutions and Provider Services segments. Adjusted EBITDA reached $190 million, up 45 percent year-over-year, with margins expanding to 5.3 percent.[1]
Adjusted earnings per share came in at $0.39, while cash flow from operations hit $123 million, excluding one-time divestiture fees. Net leverage improved to 2.27 times as of March 31, down from 2.99 times at year-end 2025. These results underscored operational efficiencies and successful integration of recent acquisitions, positioning the company for sustained profitability.
Pharmacy Solutions Drives outsized Growth
The Pharmacy Solutions segment generated $3.2 billion in revenue, a 25 percent rise year-over-year, accounting for the bulk of overall top-line expansion. Specialty and infusion pharmacy led with $2.6 billion, up 36 percent, propelled by roughly 30 percent growth in specialty scripts, new limited distribution drug contracts, and volume increases in both acute and chronic infusion therapies. Home and community pharmacy revenue dipped 9 percent to $527 million due to Inflation Reduction Act headwinds and customer exits, though scripts grew modestly excluding those impacts.[1]
Gross profit in this segment climbed 48 percent to $301 million, while adjusted EBITDA surged 46 percent to $169 million. Margins held steady at 5.3 percent, bolstered by a 70 basis-point improvement. CEO Jon Rousseau highlighted the segment’s scale, noting coverage of one-third of acute and half of chronic U.S. infusion patients, alongside innovations like brand-to-generic shifts and fee-for-service programs.
Quality metrics remained strong, with a 92.1 percent medication possession ratio in specialty pharmacy and 94 percent patient satisfaction in infusion services. These outcomes supported payer partnerships and positioned BrightSpring to navigate reimbursement challenges effectively.
Provider Services Gains Traction Through Acquisitions
Provider Services revenue totaled $442 million, reflecting 28 percent growth. Home health stood out at $266 million, up 49 percent, including $79 million from recently acquired Amedisys and LHC Group branches expected to contribute $30 million to full-year EBITDA. Rehabilitation services increased 7 percent to $75 million on higher hours billed, while personal care edged up 4 percent to $102 million.[1]
The segment delivered gross profit of $181 million, up 35 percent, and adjusted EBITDA of $66 million, a 29 percent improvement with 14.9 percent margins. Over 91 percent of home health branches achieved four stars or higher, and hospice ranked in the top 5 percent nationally. Rousseau emphasized market share gains via scaled teams and expansions like Rehab in Motion.
Strategic Divestiture and Capital Allocation
BrightSpring completed the sale of its Community Living business to Sevita, generating $811 million in pre-tax proceeds. The company plans to apply these funds toward debt reduction and general corporate purposes, targeting net leverage in the mid-2x range long-term. This move streamlines focus on higher-margin continuing operations in pharmacy and provider services.[1]
Acquisitions played a key role, with Amedisys and LHC integrations on track. Management maintains a disciplined M&A approach, favoring $5 million to $10 million tuck-ins while keeping leverage below 3 times. Operational enhancements, including AI-driven workflows and over 700 Lean Six Sigma projects, have yielded nine-figure savings.
Guidance Lift Reflects Confidence in Momentum
Emboldened by the quarter’s results, BrightSpring raised its full-year 2026 outlook for continuing operations. Revenue guidance now spans $14.725 billion to $15.225 billion, implying 14.1 percent to 17.9 percent growth excluding the divested unit. Pharmacy Solutions projections sit at $12.85 billion to $13.3 billion, with Provider Services at $1.875 billion to $1.925 billion.[1]
Adjusted EBITDA guidance climbed to $795 million to $825 million, a 28.7 percent to 33.6 percent increase that incorporates $30 million from acquisitions. CFO Jen Phipps noted offsets from $600 million in headwinds, including $175 million from the IRA and $250 million in brand-to-generic conversions, with $15 million in planned mitigations. Sequential quarterly growth remains balanced.
| Metric | 2026 Guidance (Continuing Ops) | Prior Guidance |
|---|---|---|
| Revenue | $14.725B – $15.225B | $14.45B – $15.0B |
| Adj. EBITDA | $795M – $825M | $760M – $790M |
Navigating Headwinds While Scaling Value-Based Care
Challenges persist, including quarterly IRA impacts of about $45 million on home and community pharmacy and PBM steering pressures. Yet, BrightSpring counters with low biosimilar exposure, proactive care models, and value-based initiatives that reduce hospitalizations. Pending applications like the LEAD ACO aim to expand these efforts.
Rousseau stressed a focus on quality for complex patients, leveraging data analytics for predictive interventions. With cash flow projected near $500 million for the year, the company eyes further efficiencies and growth. Investors responded positively, sending shares higher in premarket trading, as BrightSpring solidifies its role in the evolving home health landscape.[1][3]